Status:
COMPLETED
A Study of Experimental Medication BMS-986278 Given to Healthy Participants
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Healthy Participants
Eligibility:
All Genders
21-65 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to investigate experimental medication BMS-986278 given to healthy participants.
Eligibility Criteria
Inclusion
- For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
- Participants must be in good general health in the opinion of the investigator
- Body mass index (BMI) of 18.0 to 30.0 kg/m2, inclusive, at screening; BMI = weight (kg)/height (m)2
- Body weight between 55 and 105 kg, inclusive, at screening
- Female participants must have documented proof that they are not of childbearing potential
- Participants in the Japanese cohorts must be first-generation Japanese (born in Japan, not living outside of Japan for more than 10 years, and both parents are ethnically Japanese)
Exclusion
- Women who are of childbearing potential or breastfeeding
- Any significant acute or chronic medical condition that presents a potential risk to the participant and/or that may compromise the objectives of the study, including active, or history of, liver disease, or intestinal disorder including irritable bowel syndrome
- History or presence of malignancy including hematological malignancies; participants with a history of basal cell or squamous cell carcinoma that has been treated with no evidence of recurrence within 5 years will be allowed for inclusion, as judged by the investigator
- Current or recent (within 3 months of study drug administration) gastrointestinal disease that could impact upon the absorption of study drug
- Any major surgery within 6 weeks of study drug administration
- Other protocol defined inclusion/exclusion criteria could apply
Key Trial Info
Start Date :
February 7 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 2 2019
Estimated Enrollment :
112 Patients enrolled
Trial Details
Trial ID
NCT03429933
Start Date
February 7 2018
End Date
March 2 2019
Last Update
October 1 2019
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
Groningen, Netherlands, 9728 NZ
2
Local Institution
London, United Kingdom, SE1 1YR